"Lilly's incretin drugs drove the earnings beat. Mounjaro, the company's diabetes treatment, generated $6.52 billion in quarterly revenue, up 109% year-over-year. Zepbound, its obesity medication, contributed $3.57 billion, surging 184% year-over-year. Combined, these two products accounted for the bulk of revenue growth and explain why the company's top line expanded 54% to $17.60 billion against consensus expectations of $16.07 billion. Volume increased 62% in the quarter, signaling sustained demand rather than pricing dynamics alone."
"Beyond current revenue drivers, Lilly advanced orforglipron through four additional Phase 3 trials this quarter. The company now targets global obesity submissions by year-end, positioning the next-generation incretin candidate as a potential catalyst heading into 2026. Manufacturing capacity expansion is underway. Lilly is building new facilities in Virginia and Texas while expanding its Puerto Rico site."
Eli Lilly reported a strong third quarter with revenue of $17.60 billion and adjusted EPS of $7.02, both well above expectations, and raised full-year guidance. Mounjaro and Zepbound drove core growth, generating $6.52 billion and $3.57 billion respectively, lifting revenue 54% and volume 62%. Gross profit rose 57% to $14.59 billion, operating income jumped 62% to $7.37 billion, and net income surged 475% to $5.58 billion. The company advanced orforglipron in four additional Phase 3 trials and targets global obesity submissions by year-end, while gaining FDA approval for Inluriyo. Manufacturing expansion in Virginia, Texas and Puerto Rico aims to support sustained demand.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]